Plasma β-amyloid in Alzheimer’s disease and vascular disease

Citations Over TimeTop 1% of 2016 papers

Abstract

Implementation of amyloid biomarkers in clinical practice would be accelerated if such biomarkers could be measured in blood. We analyzed plasma levels of Aβ42 and Aβ40 in a cohort of 719 individuals (the Swedish BioFINDER study), including patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), Alzheimer's disease (AD) dementia and cognitively healthy elderly, using a ultrasensitive immunoassay (Simoa platform). There were weak positive correlations between plasma and cerebrospinal fluid (CSF) levels for both Aβ42 and Aβ40, and negative correlations between plasma Aβ42 and neocortical amyloid deposition (measured with PET). Plasma levels of Aβ42 and Aβ40 were reduced in AD dementia compared with all other diagnostic groups. However, during the preclinical or prodromal AD stages (i.e. in amyloid positive controls, SCD and MCI) plasma concentration of Aβ42 was just moderately decreased whereas Aβ40 levels were unchanged. Higher plasma (but not CSF) levels of Aβ were associated with white matter lesions, cerebral microbleeds, hypertension, diabetes and ischemic heart disease. In summary, plasma Aβ is overtly decreased during the dementia stage of AD indicating that prominent changes in Aβ metabolism occur later in the periphery compared to the brain. Further, increased levels of Aβ in plasma are associated with vascular disease.

Related Papers

• → Cerebrospinal Fluid Production by the Choroid Plexus and Brain(1971)222 cited
• → “Compensated hyperosmolarity” of cerebrospinal fluid and the development of hydrocephalus(2013)52 cited
• → Transient Elevation of Granulocyte Colony-Stimulating Factor Levels in Cerebrospinal Fluid at the Initial Stage of Aseptic Meningitis in Children(1995)23 cited
• → Lipoprotein(a) in the Cerebrospinal Fluid of Neurological Patients with Blood–Cerebrospinal Fluid Barrier Dysfunction(2006)13 cited
• → Cerebrospinal Fluid Thyroxine(1969)9 cited